New Zealand markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
92.24+2.29 (+2.55%)
At close: 04:00PM EDT
92.60 +0.36 (+0.39%)
Pre-market: 08:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close89.95
Open90.81
Bid92.15 x 200
Ask92.34 x 100
Day's range90.68 - 92.40
52-week range85.21 - 125.83
Volume561,655
Avg. volume587,556
Market cap22.229B
Beta (5Y monthly)0.23
PE ratio (TTM)22.55
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 Jun 2022
1y target estN/A
  • Zacks

    BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?

    On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.

  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.